Novartis wins approval for Exelon patch

Share this article:

The FDA has approved a new patch form of Novartis' Alzheimer's disease treatment Exelon (rivastigmine transdermal system), the drugmaker said Monday. 

The patch is designed to be applied to the patient’s back, chest or upper arm and helps to maintain a steady level of the drug in the bloodstream. The Exelon patch also cuts gastrointestinal side effects such as nausea and vomiting associated with drugs in its cholinesterase inhibitor class, Novartis said.
 
The Exelon patch is expected to be available in US pharmacies soon, Novartis said in a statement.
 
Novartis is hopeful the patch will help tide the company over when it loses patent protection on Exelon pills (rivastigmine tartrate) in August. Exelon pills had sales of $171 million in the first quarter.

Exelon treats mild to moderate forms of Alzheimer’s disease, which afflicts more than 5 million people in the US.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...